脂肝合剂对大鼠非酒精性脂肪肝模型LPS/TLR4通路及胰岛素抵抗影响的实验研究
详细信息 查看官网全文
- 论文作者：牛晓骥 ; 董雪莲 ; 祝海娟 ; 祁培宏
- 年：2016
- 作者机构：青海大学;青海省中医院;
- 论文关键词：脂肝合剂 ; 非酒精性脂肪肝 ; LPS/TLR4通路 ; 肠肝轴 ; Occludin蛋白
- 会议召开时间：2016-11-25
- 会议录名称：湖南中医药大学学报2016/专集：国际数字医学会数字中医药分会成立大会暨首届数字中医药学术交流会论文集
- 语种：中文
- 分类号：R285.5;R-332
- 学会代码：HNZY
- 会议名称：国际数字医学会数字中医药分会成立大会暨首届数字中医药学术交流会
- 会议地点：中国广东珠海
- 主办单位：国际数字医学会、Digital Chinese Medicine
- 学会名称：湖南中医药大学期刊杂志社
- 页数：2
- 文件大小：2109k
- 原文格式：D
- 会议级别：全国
摘要
目的:探究脂肝合剂治疗非酒精性脂肪肝(NAFLD)的机理。方法:将造模成功并接受治疗后的Wistar大鼠取血样以及肝脏和小肠组织,检测血清LPS、血清血糖(FBG)、胰岛素(INS),肝脏TLR4、小肠Occludin蛋白等指标。结果:脂肝合剂组血清LPS、肝脏TLR4、肠道Occludin蛋白与模型组相比均有统计学差异,FBG、INS、胰岛素抵抗指标HOMA-IR与模型组相比无统计学差异。结论:LPS/TLR4通路是脂肝合剂治疗非酒精性脂肪肝的靶点之一。
引文
[1]曲颖,陆伦根.非酒精性脂肪性肝病诊断方面新进展[J].中华肝脏病杂志,2016,24(2):85-88.
[2]Terashima Y,N ishiumi S,Minami A,et al.Metabolomics-based search for therapeutic agents for non-alcoholic steatohepatitis[J].Archives o f biochemistry and biophysics.2014,555-556:55-65.
[3]Fan JG.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J].Journal of gastroenterology and hepatology.2013,28(Supplement S1):11-17.
[4]祁培宏.消脂保肝饮治疗脂肪肝的临床观察与实验研究[D].上海:上海中医药大学,1998.
[5]Lin P,Lu J,Wang Y,et al.Naturally Occurring Stilbenoid TSG Reverses NonAlcoholic Fatty Liver Diseases via Gut-Liver Axis[J].Plos one.2015,10(10):e0140346.
[6]张媛媛,李晶,迟毓婧等.肌球蛋白轻链激酶在非酒精性脂肪性肝炎小鼠模型肠黏膜屏障变化中的作用[J].中华内科杂志,2015,54(5):434-438.
[7]杨坤,田珍珍,王淑华等.LPS-TLR4信号通路在慢性酒精摄入大鼠模型肝纤维化发生中的作用及其机制[J].吉林大学学报(医学版),20 15,41(4):751-755.
[8]Sutter AG,Palanisamy AP,Lench JH,et al.Dietary Saturated Fa t Promotes Development of Hepatic Inflammation through Toll-Like Receptor 4 in Mice[J].Journal of cellular biochemistry.2016,117(7):1613-21.
[9]Miura K,Ohnishi H.Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease[J].World J Gastroenterol.2014,20(23):7381-91.
[10]Bergheim I,Weber S,Vos M,et al.Antibiotics prote ct against fructose-induced hepatic lipid accumulation in mice:role of endotoxin[J].Journal of hepatology.2008,48(6):983-92.
[2]Terashima Y,N ishiumi S,Minami A,et al.Metabolomics-based search for therapeutic agents for non-alcoholic steatohepatitis[J].Archives o f biochemistry and biophysics.2014,555-556:55-65.
[3]Fan JG.Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J].Journal of gastroenterology and hepatology.2013,28(Supplement S1):11-17.
[4]祁培宏.消脂保肝饮治疗脂肪肝的临床观察与实验研究[D].上海:上海中医药大学,1998.
[5]Lin P,Lu J,Wang Y,et al.Naturally Occurring Stilbenoid TSG Reverses NonAlcoholic Fatty Liver Diseases via Gut-Liver Axis[J].Plos one.2015,10(10):e0140346.
[6]张媛媛,李晶,迟毓婧等.肌球蛋白轻链激酶在非酒精性脂肪性肝炎小鼠模型肠黏膜屏障变化中的作用[J].中华内科杂志,2015,54(5):434-438.
[7]杨坤,田珍珍,王淑华等.LPS-TLR4信号通路在慢性酒精摄入大鼠模型肝纤维化发生中的作用及其机制[J].吉林大学学报(医学版),20 15,41(4):751-755.
[8]Sutter AG,Palanisamy AP,Lench JH,et al.Dietary Saturated Fa t Promotes Development of Hepatic Inflammation through Toll-Like Receptor 4 in Mice[J].Journal of cellular biochemistry.2016,117(7):1613-21.
[9]Miura K,Ohnishi H.Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease[J].World J Gastroenterol.2014,20(23):7381-91.
[10]Bergheim I,Weber S,Vos M,et al.Antibiotics prote ct against fructose-induced hepatic lipid accumulation in mice:role of endotoxin[J].Journal of hepatology.2008,48(6):983-92.